Clinical Trial Update: Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial at Peter MacCallum Cancer Centre is evaluating a venetoclax-ibrutinib-rituximab regimen with optional navitoclax for relapsed/refractory mantle ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Navitoclax (navitoclax)
• Rituxan (rituximab)
• Venclexta (venetoclax)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Mantle Cell Lymphoma Refractory | Phase 2 | Status: ACTIVE_NOT_RECRUITING